Metformin and its therapeutic applications in autoimmune inflammatory rheumatic disease

키워드

참고문헌 (118)

1. Foretz M, "Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus", Nat Rev Endocrinol, 15, pp.569~589 (2019)
2. Zhou G, "Role of AMP-activated protein kinase in mechanism of metformin action", J Clin Invest, 108, pp.1167~1174 (2001)
3. Shaw RJ, "The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin", Science, 310, pp.1642~1646 (2005)
4. El-Mir MY, "Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I", J Biol Chem, 275, pp.223~228 (2000)
5. Owen MR, "Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1of the mitochondrial respiratory chain", Biochem J, 348(Pt 3), pp.607~614 (2000)
6. Stephenne X, "Metformin activates AMP-activated protein kinase in primary human hepatocytes by decreasing cellular energy status", Diabetologia, 54, pp.3101~3110 (2011)
7. Foretz M, "Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1", AMPK pathway via a decrease in hepatic energy state, 2010, pp.120, 2355~2369
8. Hunter RW, "Metformin reduces liver glucose production by inhibition of fructose-1-6-bisphosphatase", Nat Med, 24, pp.1395~1406 (2018)
9. Miller RA, "Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP", Nature, 494, pp.256~260 (2013)
10. Madiraju AK, "Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase", Nature, 510, pp.542~546 (2014)
11. 김정목, "AMPK activators: mechanisms of action and physiological activities", Experimental and Molecular Medicine, 48, pp.1~12 (2016), 생화학분자생물학회
12. Long YC, "AMP-activated protein kinase signaling in metabolic regulation", J Clin Invest, 116, pp.1776~1783 (2006)
13. Towler MC, "AMP-activated protein kinase in metabolic control and insulin signaling", Circ Res, 100, pp.328~341 (2007)
14. Mihaylova MM, "The AMPK signalling pathway coordinates cell growth, autophagy and metabolism", Nat Cell Biol, 13, pp.1016~1023 (2011)
15. Blagih J, "The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo", Immunity, 42, pp.41~54 (2015)
16. Delgoffe GM, "The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment", Immunity, 30, pp.832~844 (2009)
17. Delgoffe GM, "The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2", Nat Immunol, 12, pp.295~303 (2011)
18. Speirs C, "Linking energy sensing to suppression of JAK-STAT signalling : a potential route for repurposing AMPK activators?", Pharmacol Res, 128, pp.88~100 (2018)
19. Nerstedt A, "AMP-activated protein kinase inhibits IL-6-stimulated inflammatory response in human liver cells by suppressing phosphorylation of signal transducer and activator of transcription 3(STAT3)", Diabetologia, 53, pp.2406~2416 (2010)
20. Ma CS, "Functional STAT3 deficiency compromises the generation of human T follicular helper cells", Blood, 119, pp.3997~4008 (2012)
21. Ray JP, "Transcription factor STAT3 and type I interferons are corepressive insulators for differentiation of follicular helper and T helper 1 cells", Immunity, 40, pp.367~377 (2014)
22. Avery DT, "B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans", J Exp Med, 207, pp.155~171 (2010)
23. Deenick EK, "Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells", J Exp Med, 210, pp.2739~2753 (2013)
24. Vasamsetti SB, "Metformin inhibits monocyte-to-macrophage differentiation via AMPK-mediated inhibition of STAT3 activation : potential role in atherosclerosis", Diabetes, 64, pp.2028~2041 (2015)
25. Kim J, "Metformin suppresses lipopolysaccharide(LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3(ATF-3)induction", J Biol Chem, 289, pp.23246~23255 (2014)
26. McInnes IB, "Pathogenetic insights from the treatment of rheumatoid arthritis", Lancet, 389, pp.2328~2337 (2017)
27. Bartok B, "Fibroblast-like synoviocytes : key effector cells in rheumatoid arthritis", Immunol Rev, 233, pp.233~255 (2010)
28. Firestein GS, "How important are T cells in chronic rheumatoid synovitis? : II. T cell-independent mechanisms from beginning to end", Arthritis Rheum, 46, pp.298~308 (2002)
29. Panayi GS, "Even though T-cell-directed trials have been of limited success, is there reason for optimism?", Nat Clin Pract Rheumatol, 2, pp.58~59 (2006)
30. Moran EM, "Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation : synergy with tumour necrosis factor-alpha, oncostatin M and response to biologic therapies", Arthritis Res Ther, 11, pp.R113~ (2009)
31. Sato K, "Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction", J Exp Med, 203, pp.2673~2682 (2006)
32. Valencia X, "TNF downmodulates the function of human CD4+CD25hi T-regulatory cells", Blood, 108, pp.253~261 (2006)
33. Ehrenstein MR, "Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy", J Exp Med, 200, pp.277~285 (2004)
34. Nie H, "Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis", Nat Med, 19, pp.322~328 (2013)
35. Aravena O, "Anti-TNF therapy in patients with rheumatoid arthritis decreases Th1 and Th17 cell populations and expands IFN-γ-producing NK cell and regulatory T cell subsets", Immunobiology, 216, pp.1256~1263 (2011)
36. McGovern JL, "Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy", Arthritis Rheum, 64, pp.3129~3138 (2012)
37. Samson M, "Brief report : inhibition of interleukin-6 function corrects Th17", Treg cell imbalance in patients with rheumatoid arthritis, 2012, pp.64, 2499~2503
38. Pesce B, "Effect of interleukin-6 receptor blockade on the balance between regulatory T cells and T helper type 17 cells in rheumatoid arthritis patients", Clin Exp Immunol, 171, pp.237~242 (2013)
39. Ju JH, "Modulation of STAT-3 in rheumatoid synovial T cells suppresses Th17 differentiation and increases the proportion of Treg cells", Arthritis Rheum, 64, pp.3543~3552 (2012)
40. Kang KY, "Metformin downregulates Th17 cells differentiation and attenuates murine autoimmune arthritis", Int Immunopharmacol, 16, pp.85~92 (2013)
41. Son HJ, "Metformin attenuates experimental autoimmune arthritis through reciprocal regulation of Th17", Treg balance and osteoclastogenesis, 2014, pp.2014, 973986~
42. You S, "The tumor-like phenotype of rheumatoid synovium : molecular profiling and prospects for precision medicine", Arthritis Rheumatol, 70, pp.637~652 (2018)
43. Chen K, "Metformin inhibits the proliferation of rheumatoid arthritis fibroblast-like synoviocytes through IGF-IR", PI3K, m-TOR pathway, pp.Biomed Pharmacother, 2019[DOI]
44. Chen Y, "Metformin, an AMPK activator, inhibits activation of FLSs but promotes HAPLN1 secretion", Mol Ther Methods Clin Dev, 17, pp.1202~1214 (2020)
45. Bartok B, "PI3 kinase δ is a key regulator of synoviocyte function in rheumatoid arthritis", Am J Pathol, 180, pp.1906~1916 (2012)
46. Bartok B, "Phosphoinositide 3-kinase δ regulates migration and invasion of synoviocytes in rheumatoid arthritis", J Immunol, 192, pp.2063~2070 (2014)
47. Fan KJ, "Metformin inhibits inflammation and bone destruction in collagen-induced arthritis in rats", Ann Transl Med, 8, pp.1565~ (2020)
48. Jung SM, "Cytokine-mediated bone destruction in rheumatoid arthritis", J Immunol Res, 2014, pp.263625~ (2014)
49. 김해림, "N-acetyl-l-cysteine controls osteoclastogenesis through regulating Th17 differentiation and RANKL in rheumatoid arthritis", The Korean Journal of Internal Medicine, 34(1), pp.210~219 (2019), 대한내과학회[DOI]
50. Schett G, "Bone erosion in rheumatoid arthritis : mechanisms, diagnosis and treatment", Nat Rev Rheumatol, 8, pp.656~664 (2012)
51. Indo Y, "Metabolic regulation of osteoclast differentiation and function", J Bone Miner Res, 28, pp.2392~2399 (2013)
52. Matsuoka Y, "Metformin repositioning in rheumatoid arthritis", Clin Exp Rheumatol, 39, pp.763~768 (2021)
53. Lockwood TD, "The lysosome among targets of metformin : new anti-inflammatory uses for an old drug?", Expert Opin Ther Targets, 14, pp.467~478 (2010)
54. Yan H, "Suppression of experimental arthritis through AMP-activated protein kinase activation and autophagy modulation", J Rheum Dis Treat, 1, pp.5~ (2015)
55. Jhun J, "Combination therapy with metformin and coenzyme Q10 in murine experimental autoimmune arthritis", Immunopharmacol Immunotoxicol, 38, pp.103~112 (2016)
56. Kim EK, "Metformin rescues rapamycin-induced mitochondrial dysfunction and attenuates rheumatoid arthritis with metabolic syndrome", Arthritis Res Ther, 22, pp.77~ (2020)
57. 고정희, "Distinct Urinary Metabolic Profile in Rheumatoid Arthritis Patients: A Possible Link between Diet and Arthritis Phenotype", 대한류마티스학회지, 26(1), pp.46~56 (2019), 대한류마티스학회[DOI]
58. 손경민, "Association of body composition with disease activity and disability in rheumatoid arthritis", The Korean Journal of Internal Medicine, 36(1), pp.214~222 (2021), 대한내과학회[DOI]
59. 김은경, "Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation", Experimental and Molecular Medicine, 50, pp.1~9 (2018), 생화학분자생물학회
60. Gallagher L, "Insulin-resistant pathways are associated with disease activity in rheumatoid arthritis and are subject to disease modification through metabolic reprogramming : a potential novel therapeutic approach", Arthritis Rheumatol, 72, pp.896~902 (2020)
61. El-Sayyad SM, "Metformin and omega-3 fish oil elicit anti-inflammatory effects via modulation of some dysregulated micro RNAs expression and signaling pathways in experimental induced arthritis", Int Immunopharmacol, 92, pp.107362~ (2021)
62. Park YH, "Combination of LMT-28 and metformin improves beneficial anti-inflammatory effect in collagen-induced arthritis", Pharmacology, 106, pp.53~59 (2021)
63. Lu CH, "Combination of COX-2 inhibitor and metformin attenuates rate of admission in patients with rheumatoid arthritis and diabetes in Taiwan", Medicine(Baltimore), 98, pp.e17371~ (2019)
64. Naffaa ME, "Adherence to metformin and the onset of rheumatoid arthritis : a population-based cohort study", Scand J Rheumatol, 49, pp.173~180 (2020)
65. Abdallah MS, "The AMPK modulator metformin as adjunct to methotrexate in patients with rheumatoid arthritis : a proof-of-concept, randomized, double-blind, placebo-controlled trial", Int Immunopharmacol, 95, pp.107575~ (2021)
66. Bijlsma JW, "Osteoarthritis : an update with relevance for clinical practice", Lancet, 377, pp.2115~2126 (2011)
67. Deveza LA, "Is osteoarthritis one disease or a collection of many?", Rheumatology (Oxford), 57(suppl 4), pp.iv34~iv42 (2018)
68. Reyes C, "Association between overweight and obesity and risk of clinically diagnosed knee, hip, and hand osteoarthritis : a population-based cohort study", Arthritis Rheumatol, 68, pp.1869~1875 (2016)
69. Zhuo Q, "Metabolic syndrome meets osteoarthritis", Nat Rev Rheumatol, 8, pp.729~737 (2012)
70. Veronese N, "Type 2 diabetes mellitus and osteoarthritis", Semin Arthritis Rheum, 49, pp.9~19 (2019)
71. Barnett LA, "Does metformin protect against osteoarthritis? An electronic health record cohort study", Prim Health Care Res Dev, 18, pp.623~628 (2017)
72. Lu CH, "Combination COX-2 inhibitor and metformin attenuate rate of joint replacement in osteoarthritis with diabetes : a nationwide, retrospective, matched-cohort study in Taiwan", PLoS One, 13, pp.e0191242~ (2018)
73. Schett G, "Diabetes is an independent predictor for severe osteoarthritis : results from a longitudinal cohort study", Diabetes Care, 36, pp.403~409 (2013)
74. Wang Y, "Association between metformin use and disease progression in obese people with knee osteoarthritis : data from the Osteoarthritis Initiative. A prospective cohort study", Arthritis Res Ther, 21, pp.127~ (2019)
75. Kevorkian L, "Expression profiling of metalloproteinases and their inhibitors in cartilage", Arthritis Rheum, 50, pp.131~141 (2004)
76. Davidson RK, "Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage", Arthritis Res Ther, 8, pp.R124~ (2006)
77. Abramson SB, "Osteoarthritis and nitric oxide", Osteoarthritis Cartilage, 16(Suppl 2), pp.S15~S20 (2008)
78. Attur M, "Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage : evidence for signaling via the EP4 receptor", J Immunol, 181, pp.5082~5088 (2008)
79. Roach HI, "Association between the abnormal expression of matrix-degrading enzymes by human osteoarthritic chondrocytes and demethylation of specific CpG sites in the promoter regions", Arthritis Rheum, 52, pp.3110~3124 (2005)
80. Neuhold LA, "Postnatal expression in hyaline cartilage of constitutively active human collagenase-3(MMP-13)induces osteoarthritis in mice", J Clin Invest, 107, pp.35~44 (2001)
81. Stanton H, "ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro", Nature, 434, pp.648~652 (2005)
82. Yatabe T, "Hyaluronan inhibits expression of ADAMTS4(aggrecanase-1)in human osteoarthritic chondrocytes", Ann Rheum Dis, 68, pp.1051~1058 (2009)
83. Glasson SS, "Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis", Nature, 434, pp.644~648 (2005)
84. Majumdar MK, "Double-knockout of ADAMTS-4 and ADAMTS-5 in mice results in physiologically normal animals and prevents the progression of osteoarthritis", Arthritis Rheum, 56, pp.3670~3674 (2007)
85. Schadler P, "The effect of body mass index and metformin on matrix gene expression in arthritic primary human chondrocytes", Cartilage, 13(2Suppl), pp.1004~ (2021)[DOI]
86. Li H, "Exploration of metformin as novel therapy for osteoarthritis : preventing cartilage degeneration and reducing pain behavior", Arthritis Res Ther, 22, pp.34~ (2020)
87. Feng X, "Metformin attenuates cartilage degeneration in an experimental osteoarthritis model by regulating AMPK", mTOR, 2020, pp.12, 1087~1103
88. Li J, "Metformin limits osteoarthritis development and progression through activation of AMPK signalling", Ann Rheum Dis, 79, pp.635~645 (2020)
89. Zhou S, "AMPK deficiency in chondrocytes accelerated the progression of instability-induced and ageing-associated osteoarthritis in adult mice", Sci Rep, 7, pp.43245~ (2017)
90. Thomas CM, "Chondrocyte death by apoptosis is associated with cartilage matrix degradation", Osteoarthritis Cartilage, 15, pp.27~34 (2007)
91. Carames B, "Autophagy is a protective mechanism in normal cartilage, and its aging-related loss is linked with cell death and osteoarthritis", Arthritis Rheum, 62, pp.791~801 (2010)
92. Loeser RF, "Ageing and the pathogenesis of osteoarthritis", Nat Rev Rheumatol, 12, pp.412~420 (2016)
93. Sasaki H, "Autophagy modulates osteoarthritis-related gene expression in human chondrocytes", Arthritis Rheum, 64, pp.1920~1928 (2012)
94. Wang C, "Protective effects of metformin against osteoarthritis through upregulation of SIRT3-mediated PINK1", Parkin-dependent mitophagy in primary chondrocytes, 2019, pp.12, 605~612
95. Wang C, "Metformin mitigates cartilage degradation by activating AMPK", SIRT1-mediated autophagy in a mouse osteoarthritis model, 2020, pp.11, 1114~
96. Na HS, "Metformin attenuates monosodium-iodoacetate-induced osteoarthritis via regulation of pain mediators and the autophagy-lysosomal pathway", Cells, 10, pp.681~ (2021)
97. Sellam J, "The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis", Nat Rev Rheumatol, 6, pp.625~635 (2010)
98. Dawood AF, "Metformin pretreatment suppresses alterations to the articular cartilage ultrastructure and knee joint tissue damage secondary to type 2diabetes mellitus in rats", Ultrastruct Pathol, 44, pp.273~282 (2020)
99. Zhang M, "Metformin protects chondrocytes against IL-1β induced injury by regulation of the AMPK", NF-κB signaling pathway, 2020, pp.75, 632~636
100. Park MJ, "Metformin augments anti-inflammatory and chondroprotective properties of mesenchymal stem cells in experimental osteoarthritis", J Immunol, 203, pp.127~136 (2019)
101. Tsokos GC, "New insights into the immunopathogenesis of systemic lupus erythematosus", Nat Rev Rheumatol, 12, pp.716~730 (2016)
102. 이영호, "Associations Between Circulating Interleukin-17 Levels and Systemic Lupus Erythematosus and Between Interleukin-17 Gene Polymorphisms and Disease Susceptibility: A Meta-analysis", 대한류마티스학회지, 27(1), pp.37~44 (2020), 대한류마티스학회[DOI]
103. Yin Y, "Normalization of CD4+ T cell metabolism reverses lupus", Sci Transl Med, 7, pp.274~ (2015)[DOI]
104. Yin Y, "Glucose oxidation is critical for CD4+ T cell activation in a mouse model of systemic lupus erythematosus", J Immunol, 196, pp.80~90 (2016)
105. Wang H, "Neutrophil extracellular trap mitochondrial DNA and its autoantibody in systemic lupus erythematosus and a proof-of-concept trial of metformin", Arthritis Rheumatol, 67, pp.3190~3200 (2015)
106. Titov AA, "Metformin inhibits the type 1 IFN response in human CD4+ T cells", J Immunol, 203, pp.338~348 (2019)
107. Lee SY, "Metformin suppresses systemic autoimmunity in Roquinsan", san mice through inhibiting B cell differentiation into plasma cells via regulation of AMPK, STAT3, pp.J Immunol, 2017[DOI]
108. Jang SG, "Metformin enhances the immunomodulatory potential of adipose-derived mesenchymal stem cells through STAT1 in an animal model of lupus", Rheumatology(Oxford), 59, pp.1426~1438 (2020)
109. Cornaby C, "Efficacy of the combination of metformin and CTLA4Ig in the(NZB × NZW)F1 mouse model of lupus nephritis", Immunohorizons, 4, pp.319~331 (2020)
110. Sun F, "Effects of metformin on disease flares in patients with systemic lupus erythematosus : post hoc analyses from two randomised trials", Lupus Sci Med, 7, pp.e000429~ (2020)
111. Kim JW, "Metformin improves salivary gland inflammation and hypofunction in murine Sjögren’s syndrome", Arthritis Res Ther, 21, pp.136~ (2019)
112. Karatas A, "Secukinumab and metformin ameliorate dermal fibrosis by decreasing tissue interleukin-17levels in bleomycin-induced dermal fibrosis", Int J Rheum Dis, 24, pp.795~802 (2021)
113. Moon J, "Metformin ameliorates scleroderma via inhibiting Th17 cells and reducing mTOR-STAT3signaling in skin fibroblasts", J Transl Med, 19, pp.192~ (2021)
114. Ursini F, "Oral metformin ameliorates bleomycin-induced skin fibrosis", J Invest Dermatol, 136, pp.1892~1894 (2016)
115. Wang Y, "Metformin attenuates bleomycin-induced scleroderma by regulating the balance of Treg", Teffcells and reducing spleen germinal center formation, 2019, pp.114, 72~80
116. Qin X, "Effect of metformin on ossification and inflammation of fibroblasts in ankylosing spondylitis : an in vitro study", J Cell Biochem, 119, pp.1074~1082 (2018)
117. Vazirpanah N, "mTOR inhibition by metformin impacts monosodium urate crystal-induced inflammation and cell death in gout : a prelude to a new addon therapy?", Ann Rheum Dis, 78, pp.663~671 (2019)
118. Lv Z, "Metformin and its benefits for various diseases", Front Endocrinol(Lausanne), 11, pp.191~ (2020)

관련 논문AI추천